Loading
A phase 1/2 trial of 1.0% IP-001 for Injection in colorectal cancer, non-small-cell lung cancer and sarcomas, run by Immunophotonics, Inc., active and no longer recruiting.
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS is a phase 1/2 interventional study registered as NCT05688280 by Immunophotonics, Inc., with 42 participants enrolled, started 2022-11-29 and due to reach its primary completion in 2025-02. Interventions recorded: 1.0% IP-001 for Injection.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Sarcomas (soft tissue, bone, GIST) and the tag pipeline.
Shares Colorectal cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.